The mouse model of psoriasis-like skin inflammation treated with IL-22-neutralizing antibodies could relieve inflammation, however treated with IL-22BP could aggravate disease in inflammatory bowel disease (IBD) model [45, 46]. This evidence concerns the gene IL22 and psoriasis.